Figure 1 | Scientific Reports

Figure 1

From: Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Figure 1

Drug response data from Genomics Drug Sensitivity in Cancer (GDSC) were compiled from the GDSC1 (n = 791) and GDSC2 (n = 756) datasets, and merged into a single dataset containing 860 cancer cell lines (duplicates found in both datasets were excluded). (a) Pie charts depicting the number (and percentage) of cell lines associated with each organ system. Venn diagram showing the number of cancer cell lines classified as (b) bortezomib-sensitive (n = 84) and (c) bortezomib-insensitive (n = 80) based on the logarithmic half-maximal inhibitory concentration (LNIC50: < -6 for sensitivity and > -3 for insensitivity) and/or area under the curve (AUC: < 0.6 for sensitivity and > 0.9 for insensitivity) values. Boxplots depicting sensitivity to bortezomib according to (d) LNIC50 and (e) AUC, with the red horizontal lines illustrating thresholds for bortezomib-sensitivity (LNIC50 < -6 and AUC < 0.6) and insensitivity (LNIC50 > -3 and AUC > 0.9). Using both LNIC50 and AUC values, 49 bortezomib-sensitive and 38 bortezomib-insensitive cell lines were identified for use in subsequent analyses.

Back to article page